Mayne Pharma Group Limited announced it has launched an authorised generic (AG) of one of the larger dermatology products in the United States. Mayne Pharma entered into a license and supply agreement with one of the larger dermatology companies to distribute this product in non-retail channels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 AUD | -1.97% | -2.11% | +13.33% |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.33% | 378M | |
+20.21% | 43.75B | |
+27.47% | 22.06B | |
+14.75% | 14.46B | |
+13.26% | 13.62B | |
+39.44% | 11.61B | |
-9.54% | 6.9B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+9.64% | 5.32B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Expands U.S Dermatology Portfolio